Last updated on May 2018

UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

Brief description of study

This is a phase 3, randomized, multi-center, double-blinded, active-controlled study that is primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/ IV placebo in subjects with relapsing MS.

Clinical Study Identifier: TX204946

Find a site near you

Start Over